- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT03936257
Effect of an Innovative BIO Formula Intake on Infant Growth and Tolerance From 0 to 6 Months (TRUEGREEN)
Evaluation of an Innovative BIO Formula Based on a New Whey Extraction Process on the Growth and Tolerance of Infants From 0 to 6 Months.
From birth to 5 months, milk is the essential and unique food of the newborn. The French National Nutrition Program (PNNS) recommends exclusive breastfeeding "up to 6 months and at least 4 months for a healthy benefit". However, only 36% of infants 0-6 months of age are exclusively breastfed worldwide. Some mothers choose to give infant formula to their baby in the first few months of life. This decision may be a personal choice or be imposed by pathophysiological situations.
The nutritional requirements of the infant are specific, which implies adequate nutrition. Infant formulas and follow-up formulas are therefore complex products, specially developed for a group of vulnerable consumers. In fact, the compositional and information requirements for infant formula are highly regulated.
This study, defined as a pilot study, proposes to evaluate the innovative "TrueGreen" BIO infant formula based on a new whey extraction method on the growth and tolerance of infants from 0 to 6 months compared to the conventional BIO infant formula. As no growth and tolerance data are currently available for this new TrueGreen BIO formula, this study aims to determine them.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Nord
-
Lille, Nord, France, 59019
- NutrInvest - Institut Pasteur de Lille
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- 0 to 3 weeks
- Child followed by a general practitioner or pediatrician
- Informed consent form signed by the legal representatives of the subject
- Commitment of legal representatives to follow the constraints generated by the study
- Insured
Exclusion Criteria:
- Infant born prematurely before 37 weeks of amenorrhea
- Child allergic to cow's milk proteins
- Pathological pregnancy (hypertension, infection, gestational diabetes, etc.);
- Chronic or acute illness (metabolic or neuromuscular diseases, epilepsy, asthma, diabetes, digestive, renal, cardiac or haematological diseases);
- Incapacity for the legal representative(s) to understand or adhere to the protocol
- Subject involved in another clinical study or in an exclusion period from another study
- Legal representatives deprived of liberty
- Legal representatives in a position to judicial protection
- Weight of the subject according to age and sex, not included between the 3rd and the 97th percentile of the WHO Child Growth Standards
- Subject height according to age and sex, not between the 3rd and the 97th percentile of the WHO Child Growth Standards
- BMI of the subject according to age and sex, not included between the 3rd and the 97th percentile of the WHO Child Growth Standards
- Head circumference of the subject according to age and sex, not included between the 3rd and the 97th percentile of the WHO (World Health Organization) Child Growth Standards
- The investigator considers that the state of health or the concomitant treatments are not compatible with the good progress of the clinical study.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Autre
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Comparateur placebo: Breast milk
group receiving breastfeeding
|
Infants were breastfed during 3 months minimum.
Data on growth and tolerance were collected.
10 out of 40 infants take a blood test to metabolome analysis
|
Comparateur actif: infant formula conventional BIO
infant formula with conventional whey BIO
|
Infant were fed during 6 months with a conventional BIO infant formula.
Data on growth and tolerance were collected.
10 out of 40 infants take a blood test to metabolome analysis
|
Comparateur actif: infant formula BIO TrueGreen
infant formula with whey BIO TrueGreen
|
Infant were fed during 6 months with the TrueGreen BIO infant formula.
Data on growth and tolerance were collected.
10 out of 40 infants take a blood test to metabolome analysis
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Evolution of growth of infants
Délai: from 0 to 6 months
|
Weight in kilograms
|
from 0 to 6 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Height evolution of infants
Délai: from 0 to 6 months
|
data in centimeters
|
from 0 to 6 months
|
BMI evolution of infants
Délai: from 0 to 6 months
|
data in kg/m²
|
from 0 to 6 months
|
Head circumference evolution of infants
Délai: from 0 to 6 months
|
data in centimeters
|
from 0 to 6 months
|
Number of colic per day
Délai: from 0 to 6 months
|
Evaluation during 3 consecutives days every month.
|
from 0 to 6 months
|
Consistency of stool
Délai: from 0 to 6 months
|
Evaluation during 3 consecutive days every month via Bristol scale. According to the bristol scale, seven types of stool are considered: Type 1: Separate hard lumps, like nuts (hard to pass) Type 2: Sausage-shaped, but lumpy Type 3: Like a sausage but with cracks on its surface Type 4: Like a sausage or snake, smooth and soft Type 5: Soft blobs with clear cut edges (easy to pass) Type 6: Fluffy pieces with ragged edges, a mushy stool Type 7: Watery, no solid pieces, entirely liquid The mean of stool type during 3 days is considered. |
from 0 to 6 months
|
Number of regurgitation
Délai: from 0 to 6 months
|
Evaluation during 3 consecutive days every month via Vandenplas scale. According to the Vandenplas scale, seven score are considered: 0 0-2 episodes/day
The mean of score during 3 days is considered. |
from 0 to 6 months
|
Number of wake up per night
Délai: from 0 to 6 months
|
Evaluation during 3 consecutive days every month.
|
from 0 to 6 months
|
Total sleep time per day
Délai: from 0 to 6 months
|
Time in hours.
Evaluation during 3 consecutive days every month.
|
from 0 to 6 months
|
Plasma amino acid profile
Délai: between 3rd and 4th month
|
Methods : Liquid Chromatography and Tandem Mass Spectrometry (LC / MS / MS) List of amino acids : Taurine, Aspartic acid, Threonine, Serine, Asparagine, Glutamine acid, Glutamine, Glycine, Alanine, Citrulline, Valine, Cystine, Methionine, Isoleucine, Leucine, Tyrosine, Phenylalanine, Beta aminoisobutyric acid, Ornithine, 1-Methyl-Histidine, Histidine, Lysine, 3-methyl-Histidine, Arginine, Hydroxyproline, Proline
|
between 3rd and 4th month
|
Metabolomic analysis from plasma and urine samples
Délai: between 3rd and 4th month
|
Non-targeted analysis : evaluation of all small molecules in biological system, such as amino acids, sugars, alcohols, sugar phosphates, amines, fatty acids, polar lipids, hormones and vitamins, as well as specialized metabolites, such as phenolic compounds, flavonoids, monoterpenes, sesquiterpenes, polyketides, alkaloids, including xenobiotics. Methods : Liquid Chromatography and Mass Spectrometry (LC / MS) |
between 3rd and 4th month
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Autres numéros d'identification d'étude
- 2018-A00732-53
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Développement de l'enfant
-
RenJi HospitalComplétéRapport numération plaquettaire/diamètre de la rate | Classification de Child-PughChine
-
Stanford UniversityNational Cancer Institute (NCI)RésiliéCarcinome hépatocellulaire récurrent | Classe A de Child-Pugh | Classe B de Child-PughÉtats-Unis, Japon
-
Boehringer IngelheimPlus disponibleMaladies pulmonaires interstitielles (chez les populations pédiatriques) | Maladie pulmonaire interstitielle de l'enfant (CHILD)
-
Ohio State University Comprehensive Cancer CenterVarian Medical SystemsComplétéClasse A de Child-Pugh | Carcinome hépatocellulaire de stade IIIA | Carcinome hépatocellulaire de stade IIIB | Carcinome hépatocellulaire de stade IIIC | Carcinome hépatocellulaire de stade IVA | Carcinome hépatocellulaire de stade IVB | Classe B de Child-PughÉtats-Unis
-
Centre Hospitalier Universitaire DijonComplétéCarcinome hépatocellulaire de Child-Pugh AFrance
-
Roswell Park Cancer InstituteMerck Sharp & Dohme LLCActif, ne recrute pasCarcinome hépatocellulaire adulte avancé | Classe A de Child-Pugh | Carcinome hépatocellulaire de stade III | Carcinome hépatocellulaire de stade IIIA | Carcinome hépatocellulaire de stade IIIB | Carcinome hépatocellulaire de stade IIIC | Carcinome hépatocellulaire de stade IV | Carcinome hépatocellulaire... et d'autres conditionsÉtats-Unis
-
AstraZenecaRésiliéCancer de l'estomac | Malignités solides avancées | Tumeur solide | Carcinome hépatocellulaire avancé de Child-Pugh A à B7 | NSCLC EGFR et/ou mutant ROS | Carcinome des métastases pulmonairesCorée, République de